CTRI/2014/10/005077进行中（未招募）未知
A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, study to evaluate the safety, efficacy and tolerability of PreLipid®, a twice-daily supplement in subjects with higher than normal blood lipid levels
Preemptive Meds Private Limited0 个研究点目标入组 210 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Newly diagnosed Male or Female participants with higher than normal cholesterol levels defined by the American Heart Association, National Cholesterol Education Program (NCEP) and ATP-III goals for LDL cholesterol and cut off points for therapeutic lifestyle changes (TLCs) and drug therapy in different risk categories:
- •Age >= 18 years to <= 65 years
- •ï??LDL cholesterol levels >140mg/dl but <190mg/dl CHD)
- •ï??Participants who are on Atorvastatin 10 mg daily treatment with life style modification program for at least last 03 months and have LDL-C i.e >140 mg/dl with 0-2 risk factor
- •ï??Ability to understand and willingness to sign and date a written Informed Consent Document at the screening visit before any protocol- specific procedures are performed and willing to adhere to the protocol and entire trial procedures
排除标准
- •ï??Stroke, myocardial infarction, coronary artery bypass graft (CABG) percutaneous transluminal coronary angioplasty (PTCA) or angina pectoris within the last 12 months.
- •ï??Cardiac status New York Heart Association class III-IV
- •ï??Uncotrolled blood pressure 150 mmhg systolic and 100 mmhg diastolic
- •ï??Impaired renal function as shown by but not limited to serum creatinine >= 1.5 mg/dl for males and >= 1.4 mg/dl for female
- •ï??Clinically significant peripheral edema
- •ï??Clinical evidence of active liver disease or serum alenine aminotransferase (ALT) or aspartate amino transferase (AST) 2.5 times the upper limit of the normal range (2.5 X ULN)
- •ï??Participants on steroid
- •ï??Pregnancy or lactating women
- •ï??Known hypersensitivity to any of the study drugs
- •ï??Any malignancy within the last 5 years, with exception of adequately treated basal or squamous cell carcinoma of the skin or adequately treated carcinoma insitu.
- •ï??Current addiction or current alcohol abuse or history of substance or alcohol abuse within the last 2 years
- •ï??Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- •ï??Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study. Subject unlikely to comply with protocol e.g. uncooperative attitude, inability to return for follow up visits and unlikelihood completing of the study
- •ï??Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with the completion of the study evaluation.
研究者
相似试验
进行中（未招募）
1 期
Investigation on the effect and tolerability of erenumab in trigeminal neuralgiaMedDRA version: 20.0Level: PTClassification code 10044652Term: Trigeminal neuralgiaSystem Organ Class: 10029205 - Nervous system disordersTrigeminal neuralgiaEUCTR2019-000848-95-DKDansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup80
进行中（未招募）
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyMedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2016-001654-18-ESBristol-Myers Squibb International Corporation160
进行中（未招募）
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2016-001654-18-NLF. Hoffmann-La Roche Ltd166
进行中（未招募）
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2016-001654-18-FRBristol-Myers Squibb International Corporation160
已完成
2 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyJPRN-jRCT2080223587CHUGAI PHARMACEUTICAL CO., LTD.159